Home › NCT05329935

Congenital Athymia Patient Registry

Congenital Athymia Patient Registry of RETHYMIC

Who can join

Ages 0 to 21 · All sexes

Inclusion Criteria:

* Pediatric patients diagnosed with Congenital Athymia:

  * Who are scheduled for implantation with RETHYMIC within the next 30 days, or who were treated with RETHYMIC within the previous 60 days.
  * Who have provided written informed consent directly, or written informed consent has been provided by the patient, the parent, or legal guardian.

Exclusion Criteria:

* Written informed consent cannot be obtained.

About the study

This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC.

Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).

What is being tested

• Cultured Thymus Tissue (biological)

Sponsor: Sumitomo Pharma Switzerland GmbH · Participants: 75 · Started: May 25, 2022

Contact the study team

• John Sleasman, M.D. · Phone: 919-684-9914

Official record on ClinicalTrials.gov — NCT05329935

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.